Atopic Dermatitis
Lebrikizumab shows early efficacy in atopic dermatitis for patients with skin of color
SAN DIEGO — Atopic dermatitis improvement was found with lebrikizumab treatment in patients with skin of color, according to interim study results presented at the American Academy of Dermatology Annual Meeting.
Acid-suppressive medications in infancy associated with food allergy risks
WASHINGTON — Infants who were exposed to acid-suppressive medications had increased risk for developing food allergy, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Upadacitinib improves vitiligo among patients without reaching plateau for 1 year
SAN DIEGO — Patients with nonsegmental vitiligo continually improved with upadacitinib treatment up to 1 year, according to a speaker at the American Academy of Dermatology Annual Meeting.
Nemolizumab shows long-term efficacy in treatment of prurigo nodularis, atopic dermatitis
SAN DIEGO — At the American Academy of Dermatology Annual Meeting, Galderma announced new data demonstrating nemolizumab’s long-term efficacy in treating prurigo nodularis and atopic dermatitis, according to a press release.
Roflumilast improves atopic dermatitis symptoms in children aged 2 to 5 years
SAN DIEGO — In children aged 2 to 5 years with atopic dermatitis, roflumilast cream 0.05% significantly improved symptoms compared with vehicle, with improvement seen as early as 1 week after treatment, according to a speaker here.
Vtama cream achieves consistent efficacy in atopic dermatitis across racial groups
SAN DIEGO — New data showed Vtama cream achieved consistent and strong efficacy for the treatment of atopic dermatitis across all racial groups, according to a poster presentation at the 2024 American Academy of Dermatology Annual Meeting.
Atopic dermatitis treatments with greatest efficacy may also cause most harm
WASHINGTON — The most effective treatments for atopic dermatitis may also be the most harmful, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Arcutis, Sato enter licensing agreement for roflumilast in Japan
Arcutis has entered into a licensing agreement with Sato Pharmaceutical Co. Ltd. to develop, manufacture and commercialize topical roflumilast in Japan for the treatment of multiple skin conditions, according to a company press release.
Targeting aryl hydrocarbon receptor represents novel approach to atopic dermatitis therapy
The efficacy of tapinarof cream 1% has validated the aryl hydrocarbon receptor as a therapeutic target for the treatment of atopic dermatitis, according to a study.
Skin microbiota predicts atopic dermatitis in infants
WASHINGTON — Atopic dermatitis can be predicted in children aged as young as 6 months with skin microbiome and metabolome signatures, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.